Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03330028
Recruitment Status : Active, not recruiting
First Posted : November 6, 2017
Last Update Posted : April 9, 2019
Sponsor:
Information provided by (Responsible Party):
M.D. Anderson Cancer Center

Brief Summary:

The goal of this clinical research study is to find the highest tolerable dose of paclitaxel that can be given as hyperthermic intraperitoneal chemotherapy (HIPEC) to patients with gastric or gastroesophageal cancer. HIPEC is a system in which heated chemotherapy is delivered directly inside the abdomen during surgery. In this study, paclitaxel is being combined with mitomycin and cisplatin to see if this study drug combination can help to control the disease.

This is an investigational study. Mitomycin, cisplatin, and paclitaxel are FDA-approved and commercially available for the treatment of gastric and gastroesophageal cancer. It is investigational to give these drugs by HIPEC.

The study doctor can describe how the study drugs and HIPEC are designed to work.

Up to 48 participants will be enrolled in this study. All will take part at MD Anderson.


Condition or disease Intervention/treatment Phase
Diseases of Oesophagus Stomach and Duodenum Drug: Dexamethasone Drug: Diphenhydramine Drug: Famotidine Drug: Mitomycin C Drug: Cisplatin Drug: Paclitaxel Phase 1

  Show Detailed Description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 48 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Study of Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology
Actual Study Start Date : October 27, 2017
Estimated Primary Completion Date : April 2022
Estimated Study Completion Date : April 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Fever

Arm Intervention/treatment
Experimental: Hyperthermic Intraperitoneal Chemoperfusion (HIPEC)
Participants receive heated Mitomycin, Cisplatin, and Paclitaxel as a liquid that is injected through 3 to 4 small incisions into the abdomen over about 1 hour.
Drug: Dexamethasone
10 mg by vein approximately 60 minutes before Paclitaxel.
Other Name: Decadron

Drug: Diphenhydramine
50 mg by vein approximately 60 minutes before Paclitaxel.
Other Name: Benadryl

Drug: Famotidine
20 mg by vein approximately 60 minutes before Paclitaxel.
Other Name: Pepcid

Drug: Mitomycin C
Mitomycin C 30 mg in 3-7 liters of infusate administered using a rolling pump with hyperthermia for approximately 60 minutes through 3 to 4 small incisions in abdomen.
Other Name: Mitomycin

Drug: Cisplatin
Cisplatin 200 mg in 3-7 liters of infusate administered using a rolling pump with hyperthermia for approximately 60 minutes through 3 to 4 small incisions in abdomen.
Other Names:
  • Platinol-AQ
  • Platinol
  • CDDP

Drug: Paclitaxel

Starting dose of Paclitaxel is 20 mg/m2 in 3-7 liters of infusate administered using a rolling pump with hyperthermia for approximately 60 minutes through 3 to 4 small incisions in abdomen.

Dose-escalation scheme of Paclitaxel is in increments of 5 mg/m2.

Other Name: Taxol




Primary Outcome Measures :
  1. Maximum Tolerated Dose (MTD) of Paclitaxel via Intraperitoneal Route Combined with Fixed Doses of Mitomycin and Cisplatin during Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) [ Time Frame: 3 to 7 days after Hyperthermic Intraperitoneal Chemotherapy (HIPEC) infusion ]
    MTD selected based on isotonic regression as specified per methods by Liu and Yuan.

  2. Dose Limiting Toxicity (DLT) of Paclitaxel via Intraperitoneal Route Combined with Fixed Doses of Mitomycin and Cisplatin during Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) [ Time Frame: Within 21 days after Hyperthermic Intraperitoneal Chemotherapy (HIPEC) infusion ]
    Dose limiting toxicity (DLT) graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) by organ system. DLT defined as any grade III/IV non-hematologic or neutropenia-associated (infection or fever treated in the hospital) toxicity attributable to this therapy.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age 18 years and above. There will be no upper age restriction.
  2. Eastern Cooperative Oncology Group (ECOG) performance status </= 2.
  3. Cytologic or histologic proof of adenocarcinoma of the stomach or gastroesophageal junction.
  4. Adequate renal, and bone marrow function: a. Leukocytes >= 3,000/uL b. Absolute neutrophil count >= 1,500/uL c. Platelets >= 60,000/Ul d. Serum creatinine <= 1.5 mg/dL
  5. Distant Metastatic Disease of peritoneum: a. Positive peritoneal cytology b. Carcinomatosis on diagnostic laparoscopy or laparotomy.
  6. Completion of preoperative systemic chemotherapy.

Exclusion Criteria:

  1. Infections such as pneumonia or wound infections that would preclude protocol therapy.
  2. Women with a positive urine or serum pregnancy test are excluded from this study; women of childbearing potential (defined as those who have not undergone a hysterectomy or who have not been postmenopausal for at least 24 consecutive months) must agree to refrain from breast feeding and practice adequate contraception as specified in the informed consent. Adequate contraception consists of oral contraceptive, implantable contraceptives, injectable contraceptives, a double barrier method, or abstinence.
  3. Subjects with unstable angina or New York Heart Association Grade II or greater congestive heart failure.
  4. Subjects deemed unable to comply with study and/or follow-up procedures.
  5. Subjects with a known hypersensitivity to protocol systemic chemotherapy that was life-threatening, required hospitalization or prolongation of existing hospitalization, or resulted in persistent or significant disability or incapacity.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03330028


Locations
Layout table for location information
United States, Texas
University of Texas MD Anderson Cancer Center
Houston, Texas, United States, 77030
Sponsors and Collaborators
M.D. Anderson Cancer Center
Investigators
Layout table for investigator information
Principal Investigator: Brian D. Badgwell, MD M.D. Anderson Cancer Center

Additional Information:
Layout table for additonal information
Responsible Party: M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier: NCT03330028     History of Changes
Other Study ID Numbers: 2017-0232
NCI-2018-01035 ( Registry Identifier: NCI CTRP )
First Posted: November 6, 2017    Key Record Dates
Last Update Posted: April 9, 2019
Last Verified: April 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Keywords provided by M.D. Anderson Cancer Center:
Famotidine
Pepcid
Diseases of oesophagus stomach and duodenum
Gastric cancer
Gastroesophageal cancer
Adenocarcinoma of the stomach or gastroesophageal junction
Hyperthermic intraperitoneal chemotherapy
HIPEC
Paclitaxel
Taxol
Dexamethasone
Decadron
Diphenhydramine
Benadryl
Cisplatin
Platinol-AQ
Platinol
CDDP
Mitomycin-C
Mitomycin

Additional relevant MeSH terms:
Layout table for MeSH terms
Famotidine
Adenocarcinoma
Carcinoma
Esophageal Diseases
Fever
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Body Temperature Changes
Signs and Symptoms
Gastrointestinal Diseases
Digestive System Diseases
Diphenhydramine
Promethazine
Dexamethasone
Dexamethasone acetate
Paclitaxel
Albumin-Bound Paclitaxel
Cisplatin
Mitomycins
Mitomycin
BB 1101
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Anti-Inflammatory Agents
Antiemetics